Skip to main content

Table 1 Baseline patient characteristics and treatment

From: Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

   Patients (N = 208) n
Age (y/o) Median 69 (48–90)   
  Age ≤ 60 12.5% 26
  60 < Age ≤ 70 46.2% 96
  Age > 70 41.3% 86
Race White 54.8% 114
  Black 38.0% 79
  Other 7.2% 15
Charlson Comorbidity Index CCI = 0 68.3% 142
  CCI = 1 22.6% 47
  CCI ≥ 2 9.1% 19
Body Mass Index (BMI) Median 27.34 (15.02-44.96)   
  BMI ≥ 30 29.3% 61
Partner Status Married or Partnered 76.4% 159
  Not Partnered 23.6% 49
Employment Status Working 47.6% 99
  Not Working 52.4% 109
Median Prostate Volume (cc) Median 38.6 (11.6-138.7) cc   208
Baseline AUA Score Median 7 (0 – 34)   141
Procedure for BPH   11.5% 24
α 1A inhibitor usage   27.4% 57
Anticoagulant usage   32.2% 67
Risk Groups (D’Amico’s) Low 39.4% 82
  Intermediate 52.4% 109
  High 8.2% 17
ADT   14.4% 30
SBRT Dose 36.25 Gy 87.5% 182
  35 Gy 12.5% 26